Development of bioluminescence imaging of respiratory syncytial virus (RSV) in virus-infected live mice and its use for evaluation of therapeutics and vaccines

Vaccine

Volumn 35, Issue 4, 2017, Pages 694-702

  Fuentes, Sandra ^a   Arenas, Diego ^a   Moore, Martin M ^b   Golding, Hana ^a   Khurana, Surender ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Animal model; Antibody; Efficacy; F protein; Immune complex; Live imaging. Ds Cav1; Neutralization; Palivizumab; Pre fusion F; RSV; Therapeutic; Treatment; Vaccine

Indexed keywords

ADJUVANTED RECOMBINANT PRE FUSION F PROTEIN; FIREFLY LUCIFERASE; NEUTRALIZING ANTIBODY; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS ENZYME; VIRUS RNA; ANTIVIRUS AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BIOLUMINESCENCE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMAGING; IMAGING SYSTEM; IMMUNIZATION; IN VITRO STUDY; LUNG; MOUSE; NONHUMAN; NOSE CAVITY; PLAQUE ASSAY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; VACCINATION; VIRION; VIRUS IMMUNITY; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; WHOLE BODY BIOLUMINESCENCE IMAGING; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; EVALUATION STUDY; GENETICS; INTRAVITAL MICROSCOPY; ISOLATION AND PURIFICATION; LUMINESCENCE; PNEUMOVIRUS; PROCEDURES; REPORTER GENE; STAINING; TREATMENT OUTCOME; VIROLOGY; WHOLE BODY IMAGING;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; FEMALE; GENES, REPORTER; INTRAVITAL MICROSCOPY; LUCIFERASES, FIREFLY; LUMINESCENT MEASUREMENTS; LUNG; MICE, INBRED BALB C; NASAL CAVITY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIRATORY SYNCYTIAL VIRUSES; STAINING AND LABELING; TREATMENT OUTCOME; VIRAL LOAD; WHOLE BODY IMAGING;

EID: 85008312169     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.11.044     Document Type: Article

References (22)

1. [1] Kim, H.W., Canchola, J.G., Brandt, C.D., Pyles, G., Chanock, R.M., Jensen, K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89 (1969), 422–434.
2. [2] Jorquera, J.I., Safety procedures of coagulation factors. Haemophilia 13:Suppl 5 (2007), 41–46.
3. [3] Moore, M.L., Chi, M.H., Luongo, C., Lukacs, N.W., Polosukhin, V.V., Huckabee, M.M., et al. A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J Virol 83 (2009), 4185–4194.
4. [4] Tripp, R.A., Moore, D., Jones, L., Sullender, W., Winter, J., Anderson, L.J., Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J Virol 73 (1999), 7099–7107.
5. [5] Zaitseva, M., Kapnick, S.M., Scott, J., King, L.R., Manischewitz, J., Sirota, L., et al. Application of bioluminescence imaging to the prediction of lethality in vaccinia virus-infected mice. J Virol 83 (2009), 10437–10447.
6. [6] Zaitseva, M., Shotwell, E., Scott, J., Cruz, S., King, L.R., Manischewitz, J., et al. Effects of postchallenge administration of ST-246 on dissemination of IHD-J-Luc vaccinia virus in normal mice and in immune-deficient mice reconstituted with T cells. J Virol 87 (2013), 5564–5576.
7. [7] Zaitseva, M., McCullough, K.T., Cruz, S., Thomas, A., Diaz, C.G., Keilholz, L., et al. Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus. J Virol 89 (2015), 3295–3307.
8. [8] McLellan, J.S., Chen, M., Joyce, M.G., Sastry, M., Stewart-Jones, G.B., Yang, Y., et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342 (2013), 592–598.
9. [9] Mejias, A., Chavez-Bueno, S., Rios, A.M., Saavedra-Lozano, J., Fonseca Aten, M., Hatfield, J., et al. Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob Agents Chemother 48 (2004), 1811–1822.
10. [10] Saez-Llorens, X., Moreno, M.T., Ramilo, O., Sanchez, P.J., Top, F.H. Jr., Connor, E.M., et al. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J 23 (2004), 707–712.
11. [11] Fuentes, S., Coyle, E.M., Golding, H., Khurana, S., Nonglycosylated G-protein vaccine protects against homologous and heterologous respiratory syncytial virus (RSV) challenge, while glycosylated G enhances RSV lung pathology and cytokine levels. J Virol 89 (2015), 8193–8205.
12. [12] Ngwuta, J.O., Chen, M., Modjarrad, K., Joyce, M.G., Kanekiyo, M., Kumar, A., et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med, 7, 2015, 309ra162.
13. [13] Feltes, T.F., Cabalka, A.K., Meissner, H.C., Piazza, F.M., Carlin, D.A., Top, F.H. Jr., et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 143 (2003), 532–540.
14. [14] Mejias, A., Chavez-Bueno, S., Rios, A.M., Aten, M.F., Raynor, B., Peromingo, E., et al. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob Agents Chemother 49 (2005), 4700–4707.
15. [15] Fuentes, S., Crim, R.L., Beeler, J., Teng, M.N., Golding, H., Khurana, S., Development of a simple, rapid, sensitive, high-throughput luciferase reporter based microneutralization test for measurement of virus neutralizing antibodies following Respiratory Syncytial Virus vaccination and infection. Vaccine 31 (2013), 3987–3994.
16. [16] Varada, J.C., Teferedegne, B., Crim, R.L., Mdluli, T., Audet, S., Peden, K., et al. A neutralization assay for respiratory syncytial virus using a quantitative PCR-based endpoint assessment. Virol J, 10, 2013, 195.
17. [17] Zaitseva, M., Kapnick, S.M., Meseda, C.A., Shotwell, E., King, L.R., Manischewitz, J., et al. Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organs. J Virol 85 (2011), 9147–9158.
18. [18] Rameix-Welti, M.A., Le Goffic, R., Herve, P.L., Sourimant, J., Remot, A., Riffault, S., et al. Visualizing the replication of respiratory syncytial virus in cells and in living mice. Nat Commun, 5, 2014, 5104.
19. [19] Palomo, C., Mas, V., Thom, M., Vazquez, M., Cano, O., Terron, M.C., et al. Influence of respiratory syncytial virus F glycoprotein conformation on induction of protective immune responses. J Virol 90 (2016), 5485–5498.
20. [20] McLellan, J.S., Chen, M., Leung, S., Graepel, K.W., Du, X., Yang, Y., et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340 (2013), 1113–1117.
21. [21] Subramanian, K.N., Weisman, L.E., Rhodes, T., Ariagno, R., Sanchez, P.J., Steichen, J., et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J 17 (1998), 110–115.
22. [22] Saez-Llorens, X., Castano, E., Null, D., Steichen, J., Sanchez, P.J., Ramilo, O., et al. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group. Pediatr Infect Dis J 17 (1998), 787–791.